Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,006 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical dissection of multicentric Castleman disease.
Shin DY, Jeon YK, Hong YS, Kim TM, Lee SH, Kim DW, Kim I, Yoon SS, Heo DS, Park S, Kim BK. Shin DY, et al. Among authors: hong ys. Leuk Lymphoma. 2011 Aug;52(8):1517-22. doi: 10.3109/10428194.2011.574759. Epub 2011 May 17. Leuk Lymphoma. 2011. PMID: 21585280
ERRATUM: Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group.
Yoon S, Kim M, Hong YS, Kim HS, Kim ST, Kim J, Yun H, Yoo C, Ahn HK, Kim HS, Lee IH, Kim IH, Park I, Jeong JH, Cheon J, Kim JW, Yun J, Lim SM, Cha Y, Jang SJ, Zang DY, Kim TW, Kang JH, Kim JH. Yoon S, et al. Among authors: hong ys. Cancer Res Treat. 2023 Jul;55(3):1061. doi: 10.4143/crt.2021.1115.E. Epub 2023 Apr 21. Cancer Res Treat. 2023. PMID: 37114287 Free PMC article. No abstract available.
Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.
Kim TH, Chang HJ, Kim DY, Jung KH, Hong YS, Kim SY, Park JW, Oh JH, Lim SB, Choi HS, Jeong SY. Kim TH, et al. Among authors: hong ys. Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1158-65. doi: 10.1016/j.ijrobp.2009.06.019. Epub 2009 Sep 30. Int J Radiat Oncol Biol Phys. 2010. PMID: 19800178
Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Kang MJ, Hong YS, Kim KP, Kim SY, Baek JY, Ryu MH, Lee JL, Chang HM, Kim MJ, Chang HJ, Kang YK, Kim TW. Kang MJ, et al. Among authors: hong ys. Invest New Drugs. 2012 Aug;30(4):1607-13. doi: 10.1007/s10637-011-9703-8. Epub 2011 Jun 25. Invest New Drugs. 2012. PMID: 21706149 Clinical Trial.
1,006 results